Scilex Holding (SCLX) Long-Term Investments (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Long-Term Investments of $4.8 million for Q1 2026, down 93.89% year-over-year from $79.1 million in Q1 2025, and down 96.97% on a QoQ basis from $159.4 million in Q4 2025.
Scilex Holding (SCLX) Long-Term Investments (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Long-Term Investments for 5 consecutive years, with $4.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments fell 93.89% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (down 93.89% YoY), while the FY2025 annual figure was $159.4 million, changed N/A from the prior year.
- Long-Term Investments came in at $4.8 million for Q1 2026 at Scilex Holding, down from $159.4 million in the prior quarter.
- The five-year high for Long-Term Investments was $159.4 million in Q4 2025, with the low at $2.4 million in Q3 2024.
- Average Long-Term Investments over 4 years is $72.0 million, with a median of $79.1 million recorded in 2025.
- Across the five-year window, Long-Term Investments soared 90030473.08% in 2022 and plunged 93.89% in 2026, its largest moves.
- Year by year, Long-Term Investments stood at $101.3 million in 2022, then plunged by 97.66% to $2.4 million in 2024, then surged by 6611.71% to $159.4 million in 2025, then plunged by 96.97% to $4.8 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $4.8 million, $159.4 million, and $16.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.12 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 268.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -12.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 983.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 1.63 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -24.00 Mn |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 4.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.83 Mn |
| Dec 31, 2025 | 159.40 Mn |
| Sep 30, 2025 | 16.35 Mn |
| Jun 30, 2025 | 2.47 Mn |
| Mar 31, 2025 | 79.10 Mn |
| Sep 30, 2024 | 2.38 Mn |
| Sep 30, 2022 | 101.29 Mn |
| Jun 30, 2022 | 141.59 Mn |
| Mar 31, 2022 | 140.45 Mn |
| Dec 31, 2021 | 139.41 Mn |
| Sep 30, 2021 | 139.41 Mn |
| Jun 30, 2021 | 139.41 Mn |
| Mar 31, 2021 | 156.00 |